TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05404607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial distortion method with neuromuscular inhibition technique
Description: 27 participants will receive FDM with INIT followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fascial distortion method
Description: 27 participants will receive FDM followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
Study: NCT06398821

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: G3P-01
Description: Nutritional supplement to promote healthy aging

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: G3P-01
Description: Nutritional supplement to promote healthy aging

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: G3P-01
Description: Nutritional supplement to promote healthy aging

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05051202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugars from Fiber
Description: Proprietary blend of Sugars from Fiber baked into 50 g flapjack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugars from Fiber
Description: Proprietary blend of Sugars from Fiber baked into 50 g flapjack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugars from Fiber
Description: Proprietary blend of Sugars from Fiber baked into 50 g flapjack

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Maltodextrin
Description: Resistant Maltodextrin baked into 50 g flapjack
Study: NCT05897060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Jugular O2 Saturation optical fiber
Description: A continuous measurement of VjO2S, the usual reference measurement of the marketed devices, will be performed by implanting an optical fiber (CEVOX, PULSION Medical Systems) through an internal jugular catheter in addition to the classical catheter of the external electro-systolic drive probe. The following parameters will be recorded every 2 seconds: invasive blood pressure (systolic, mean and diastolic), heart rate, SaO2 on the pulse wave. VjO2S will be recorded continuously during the entire implantation procedure. The time of the beginning of the surgical incision, of the beginning of sinus tachycardia (overdriving) induced by external electro-systolic stimulation, of the beginning of inflation of the intravalvular aortic balloon, of the maximum occlusion of the balloon, of the end of complete deflation of the balloon, of the end of stimulation and of the end of skin closure will be recorded.
Study: NCT06046365

Intervention type: DIAGNOSTIC_TEST
Intervention: lymphoscintigraphy
Description: lymphoscintigraphy

Intervention type: DIAGNOSTIC_TEST
Intervention: circumference measurement
Description: circumference measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: sonography
Description: B-mode sono and elastography

Intervention type: DIAGNOSTIC_TEST
Intervention: DXA body composition analysis
Description: DXA body composition analysis
Study: NCT04848480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin icodec
Description: insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
Study: NCT06425510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viviendo las Ventajas de la Asistencia Tecnológica
Description: It comprises 2-hours small group sessions of 8-10 participants, once a week, for six weeks of participatory discussions, experiential learning, multimodal instructions, and demonstration and practice with selected ATDs. The content of the VIVE-AT weekly sessions is as follows: Week 1 - Introduction to ATDs, funding and resources; Week 2 - ATDs for self-care and toilet use; Week 3 - ATDs for mobility; Week 4 - ATDs for dressing; Week 6 - ATDs for cooking and home tasks. Each session is designed with the following components: monitoring of participants\&#39; weekly goals, providing information on ATDs, resources, and services, reflection on the advantages and disadvantages of using these ATDs, hands-on practice with selected ATDs, goal setting, and addressing barriers to using ATDs. Group sessions will incorporate visual aids, including modeling and videos of older individuals using ATDs accessed through an AT web app in a tablet provided by this project.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention calls
Description: Ten minutes attention calls, once a week for six weeks to the waitlist control participants will offer general health advice on topics like nutrition, exercise, sleep, stress, and social connections. These calls emphasize participant well-being without touching upon the specific VIVE-AT content, maintaining a clear distinction from the intervention group.
Study: NCT05051202

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Maltodextrin
Description: Resistant Maltodextrin baked into 50 g flapjack

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Maltodextrin
Description: Resistant Maltodextrin baked into 50 g flapjack
Study: NCT04585984

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental - Probiotic
Description: Patients in the experimental group will take one compound (pill) a day for 21 days, containing a 50% combination of two probiotics: Lactobacillus rhamnosus and Bifidobacterium longum, at a dose of 10\^9 cfu/day. The carrier of lyophilized probiotics is maltodextrin and the mixture is encapsulated in hypromellose capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will take one unit of placebo a day for 21 days.
Study: NCT05040698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Open label Fostamatinib
Study: NCT04554459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 MG Oral Tablet
Description: ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
Study: NCT06251622

Intervention type: OTHER
Intervention: Volumetric ultrasound of the quadriceps and fitting of an accelerometer
Description: The research procedure will simply involve a volumetric ultrasound of the quadriceps and the fitting of an accelerometer (watch worn on the wrist) for one week (collection of usual physical activities).
Study: NCT05434494

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remimazolam
Description: Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifantanil
Description: 25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
Study: NCT06156852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction group
Description: Mindfulness-based stress reduction (MBSR) group interventions were implemented for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral-based stress reduction group
Description: Cognitive behavioral-based stress reduction group interventions were implemented for eight weeks.
Study: NCT04847570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music session
Description: Non-clinical intervention only, and no change to clinical care or treatment. Participants will have 10 minutes of undisturbed rest, followed by a supervised music-listening session of up to 40 minutes, ending with another 10-minute rest period.
Study: NCT01153204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Psychotherapy plus Sildenafil citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Study: NCT05232084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + Fentanyl
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + Fentanyl
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study: NCT04280016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will participate in an exercise session with non-weight-bearing exercise that the participant is able to perform with off-loading (e.g. total contact cast) intact. They will also be instructed in a home exercise program so that exercise can be performed three days per week with no more than two days between sessions. These participants will also receive standard wound care with off-loading.
Study: NCT05321459

Intervention type: OTHER
Intervention: Neurological prognosis
Description: In usual practice, in intensive care unit, evaluating the neurological prognosis of comatose patients after cardiac arrest requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations (among them auditive evoked potentials or AEP).~An algorithm (PRECOM tool) which has been previously developed from the signal extracted from AEP allows to visually classify the patients after processing signal by the algorithm in a cluster of points with a high specificity into good neurological prognosis and bad neurological prognosis.~The AEP signals recorded in the 1st and 2nd week of patient inclusion are to be collected by the neurophysiologist. At the end of the patient's participation in the study, these data will be encrypted, anonymized and transmitted to the mathematician to be processed by the PRECOM tool.
Study: NCT04912544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation Mask Microphone
Description: Noninvasive Ventilation Mask Microphone is turned on to enhance speech intelligibility during the intervention portion of the crossover feasibility study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation Mask Microphone
Description: Noninvasive Ventilation Mask Microphone is turned on to enhance speech intelligibility during the intervention portion of the crossover feasibility study
Study: NCT06451367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular programm
Description: neuromuscular programm during 12 weeks (3 times a week, 10 minutes each time)
Study: NCT05820048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 15 mg
Description: 1. Short-term treatment of active duodenal ulcer~2. Short-term treatment of active benign gastric ulcers~3. Thin heat of Helicobacter pylori to prevent recurrence of duodenal ulcer~4. Maintain duodenal ulcer after treatmentLaw~5. Treatment of nonsteroidal anti-inflammatory analgesics-induced gastric ulcers~6. Reducing the risk of developing nonsteroidal anti-inflammatory analgesic-induced gastric ulcers~7. Short-term treatment of gastroesophageal reflux disease~8. Short-term treatment of erosive reflux esophagitis~9. Post-treatment maintenance therapy for erosive reflux esophagitis~10. Pathological hyperdivision, including Zolinger Ellison syndrome
Study: NCT06455878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full usage of diet management app group and with the full usage of an intelligent weight scale
Description: Subjects will use the fully functional diet management application and an intelligent weight scale with full function designed for obese heart failure patients to help them losed weight and invitigate some important composite cardiovascular endpoint.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Limited usage of diet management app group and with the limited usage of an intelligent weight scale
Description: Subjects will use the limited function diet management application and an intelligent weight scale with limited function designed for obese heart failure patients as a comparator.
Study: NCT05198076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Repetitive Transcranial Magnetic Stimulation
Description: The High Frequency repetitive TMS will be delivered to the scalp over the primary motor cortex contralateral to the more affected side using a MAGSTIM rapid2 machine (Model P/N 3576-23-09, MAGSTIM Company LTD, UK) connected with a figure - of- eight shaped coil. Each patient will receive 12 sessions over four weeks. Position of the coil will be adjusted to find the optimal scalp position and the location of stimulation that will be marked to maintain consistency among sessions. The session will consist of 24 trains of 50 stimuli each delivered at five Hz. The procedure will be conducted with the patients in the ''On'' state (75 min. after medications)
Study: NCT04972188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYIL1 Capsule
Description: NLRP3 inflammasome inhibitor
Study: NCT06306924

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Subjects with metastatic cancer receive radiation therapy.
Study: NCT05496985

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simplified Evaluation of CONsciousness Disorders (SECONDs)
Description: All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simplified Evaluation of CONsciousness Disorders (SECONDs)
Description: All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simplified Evaluation of CONsciousness Disorders (SECONDs)
Description: All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simplified Evaluation of CONsciousness Disorders (SECONDs)
Description: All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
Study: NCT05003141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSB202
Description: PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
Study: NCT05531968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMI2006
Description: IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: IM
Study: NCT04814472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-0409
Description: Randomized to active product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-0409
Description: Randomized to active product.
Study: NCT06294041

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Restriction Therapy (SRT)
Description: SRT is a manualised, adaptive, behavioural insomnia intervention that is a key active ingredient within multi-component CBT-I. Our SRT protocol involves standardising and (where required) limiting a patient's time in bed with the aim of increasing homeostatic sleep pressure, over-riding cognitive and physiological arousal, and strengthening circadian control of sleep. Those randomised to the SRT arm will receive two online sessions supported by two telephone calls over a 4-week intervention phase. The intervention will be delivered by trained research nurses

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Hygiene Education (SHE)
Description: SHE will be delivered via a booklet that provides information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). Patients in the SHE condition will be instructed to implement the SHE advice over a 4-week period. One week after randomisation to SHE, the RA will telephone patients to check they understand the SHE advice and answer any questions they may have. SHE has successfully been used as a control condition in other trials evaluating SRT and does not have any therapeutic benefit for individuals with insomnia but is often part of usual care, so is a credible alternative to SRT.
Study: NCT05965206

Intervention type: BEHAVIORAL
Intervention: Follow-up phone interview
Description: Follow-up phone interview within 7 business days after receiving intravenous chemotherapy
Study: NCT04871763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retainers' Cleansing with Geldis®
Description: Patients will clean their essix retainers with Geldis® using a toothbrush every night for 2 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retainers' Cleansing with tablets
Description: Patients will leave their essix retainers in a glass with water and Polident tablets every night for 2 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retainers' cleansing with water
Description: Patients will brush their essix retainers with a toothbrush under water every night for 2 months.
Study: NCT06431165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: After confirming patient history, type of operation and patient group allocation, standard ASA monitoring will be attached to the patient then the I.V induction of anesthesia will be commenced using standard doses of Propofol \&Tracrium in addition to 1 μg/kg Fentanyl and 1 ml/10 kg from the bolus Lidocaine syringe followed after 3 minutes by endotracheal intubation, then the Lidocaine infusion Syringe will be attached to a separate I.V line at an infusion rate of 1 ml/10 kg/h. The patient will receive 1 gm of I.V paracetamol and the surgery will be allowed to proceed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: After confirming patient history, type of operation and patient group allocation, standard ASA monitoring will be attached to the patient then the I.V induction of anesthesia will be commenced using standard doses of Propofol \&Tracrium in addition to 1 μg/kg Fentanyl and 1 ml/10 kg from the bolus Lidocaine syringe followed after 3 minutes by endotracheal intubation, then the Lidocaine infusion Syringe will be attached to a separate I.V line at an infusion rate of 1 ml/10 kg/h. The patient will receive 1 gm of I.V paracetamol and the surgery will be allowed to proceed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: After confirming patient history, type of operation and patient group allocation, standard ASA monitoring will be attached to the patient then the I.V induction of anesthesia will be commenced using standard doses of Propofol \&Tracrium in addition to 1 μg/kg Fentanyl and 1 ml/10 kg from the bolus Lidocaine syringe followed after 3 minutes by endotracheal intubation, then the Lidocaine infusion Syringe will be attached to a separate I.V line at an infusion rate of 1 ml/10 kg/h. The patient will receive 1 gm of I.V paracetamol and the surgery will be allowed to proceed.
Study: NCT06214169

Intervention type: DRUG
Group type: OTHER
Intervention: Cisatracurium Besylate
Description: Addition of cisatracurium to plain lignocaine for IVRA.

Intervention type: DRUG
Group type: OTHER
Intervention: Lignocaine
Description: Plain Lignocaine for IVRA
Study: NCT05854823

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dose-reduced radiotherapy
Description: Patients receive 50Gy/25F, 2Gy/F QD, five days a week for 5 weeks
Study: NCT04259983

Intervention type: OTHER
Intervention: Maximal exercise test
Description: The maximal exercise test will be performed on an electronically braked bicycle ergometer.

Intervention type: OTHER
Intervention: Maximal exercise test
Description: The maximal exercise test will be performed on an electronically braked bicycle ergometer.

Intervention type: OTHER
Intervention: Maximal exercise test
Description: The maximal exercise test will be performed on an electronically braked bicycle ergometer.

Intervention type: OTHER
Intervention: Endothelial dysfunction assessment
Description: Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.
Study: NCT04718740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluzoparib
Description: Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib